BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

Li Maa Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of China;b Department of Pediatrics, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, People’s Republic of ChinaView further author information

Jianwei Wangc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yang Yangc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Jun Lua Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Jing Linga Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Xinran Chua Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Zimu Zhangc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yanfang Taoc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Xiaolu Lic Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yuanyuan Tiana Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Zhiheng Lic Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yongping Zhanga Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Xu Sanga Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Lihui Lua Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Xiaomei Wana Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Kunlong Zhanga Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yanling Chenc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Juanjuan Yuc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Ran Zhuoc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Shuiyan Wud Intensive Care Unit, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Jian Panc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Xiuxia Zhouc Institute of Pediatric Research, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information

Yixin Hua Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information

Shaoyan Hua Department of Hematology, Children’s Hospital of Soochow University, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information

show all

BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date